We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Human Papillomavirus Self-Testing Proves Effective

By LabMedica International staff writers
Posted on 06 Feb 2014
Self-testing for human papillomavirus (HPV), which is one of the main causes of cervical cancer, is as effective at detecting cancer as a conventional cytology screening by smear test. More...


When self-testing is scaled up to test large populations, the number of women referred to clinics for follow-up tests rapidly increases, but the quality of clinical care then goes down, as clinics are unable to handle the high number of patients.

Scientists from Queen Mary University (London, UK) working with colleagues in Mexico, conducted a pilot study of 100,242 Mexican women aged 25 to 75 and from low-income backgrounds. Around 11% of women tested positive for HPV (10,863 women). The study began in February 2007 and patient follow-up ended in July 2010. The standard Digene conical collection brush (Qiagen Inc.; Gaithersburg, MD, USA) was used to obtain the vaginal specimens.

The High-Risk HPV DNA (hrHPV DNA) was detected with a standard commercial kit employing in vitro nucleic acid hybridization and chemiluminescent microplate-based signal amplification. The Qiagen hybrid capture (HC2) assay was conducted in a validated and accredited routine HPV testing laboratory. The HC2 relative light unit/cutoff of 1 was considered a positive test. The hrHPV positive women and a randomly selected subset of 3.2% of hrHPV negative participants serving as controls were referred to colposcopic examination for diagnosis confirmation.

The hrHPV testing of self-collected vaginal samples demonstrates a high negative predictive value (NPV) for relevant cervical disease, highlighting this test's benefit as a primary screening procedure in developing countries, as women who had a negative hrHPV result have virtually no risk of cervical intraepithelial neoplasia (CIN) 3+ lesions. Self-collected hrHPV testing may be particularly attractive for increasing screening intervals, and it appears to be an acceptable screening option in large-scale routine settings. In addition, given the magnitude of the relative risk and positive likelihood ratio, the findings demonstrate that hrHPV testing of self-collected samples is a satisfactory screening test for identification of women with target CIN2+ lesions.

Attila T. Lorincz, PhD, a professor of molecular epidemiology and lead author, said, “Our findings show that large-scale HPV screening can be successfully implemented by home testing. However, if a positive result is received, it's imperative that all other follow-up services are strengthened so they can accommodate the big increase in screened women. This is one of the huge challenges we face in developing countries like Mexico and will continue to work on.” The study was published on December 7, 2013, in the International Journal of Cancer.

Related Links:

Queen Mary University
Qiagen Inc.


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.